BioTelemetry
BioTelemetry is a mobile and wireless medical technology company providing cardiac and mobile blood-glucose monitoring, centralized medical imaging, and original equipment manufacturing, now part of Philips.
Last updated September 15, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
BioTelemetry is a mobile and wireless medical technology company focused on delivering health information to save and improve lives while reducing the cost of care. Founded a quarter century ago, it provides cardiac and mobile blood-glucose monitoring, centralized medical imaging, and original equipment manufacturing serving the healthcare and clinical research sectors. Its history traces back to CardioNet, Inc., founded in San Diego in 1994, which developed the MCOT™ mobile cardiac telemetry system and later became part of BioTelemetry. The company is now part of Philips, and its website operates as Philips Ambulatory Monitoring and Diagnostics.
History
BioTelemetry traces its origins to CardioNet, Inc., founded in San Diego in March 1994. In February 2002, CardioNet announced FDA approval of MCOT™ and opened the first CardioNet monitoring center. In February 2007, CardioNet announced the acquisition of PDSHeart, and in March 2007 the Rothman Study was published showing MCOT™ provided a significantly higher diagnostic yield compared to traditional loop event monitoring. In December 2007, CardioNet released the third generation of MCOT™ monitoring devices. In March 2008, CardioNet completed its Initial Public Offering, and in October 2008 its MCOT™ System received Category I CPT Codes and Reimbursement Rates. In November 2010, CardioNet announced a definitive merger agreement with Biotel, Inc. In December 2011, CardioNet announced the launch of its Next Generation MCOT™ Device. In 2012, CardioNet acquired ECG Scanning & Medical Services, Inc. in February and CardioCore Lab, Inc. in August, announced a clinical study supporting the efficacy of CardioNet MCOT™ in detecting atrial fibrillation in cryptogenic stroke patients in November, and launched a New Wireless Event Monitor in November. In February 2013, CardioNet, IMEC and Delta partnered to develop next generation cardiac monitoring products. BioTelemetry, founded a quarter century ago, remains committed to leading the mobile and wireless medical technology industry, focusing on the delivery of health information to save and improve lives while reducing the cost of care. Today, the company provides cardiac and mobile blood-glucose monitoring, centralized medical imaging, and original equipment manufacturing serving the healthcare and clinical research sectors. BioTelemetry is now part of Philips, and its website operates as Philips Ambulatory Monitoring and Diagnostics.
Products and positioning
Leading the mobile and wireless medical technology industry; part of Philips' patient care management ecosystem.
MCOT™ mobile cardiac telemetry
Mobile cardiac telemetry system; FDA approved in 2002; third generation released in 2007; next generation launched in 2011.
ePatch extended Holter
Extended Holter monitoring solution offered under Philips Ambulatory Monitoring and Diagnostics.
Recent events
- Unconfirmed
Philips completes acquisition of BioTelemetry[3]
Royal Philips announced that it had completed its acquisition of BioTelemetry, whose financial results would be consolidated into Philips’ Connected Care business segment as of February 9, 2021.
Philips announces agreement to acquire BioTelemetry[4]
Reported:
Royal Philips announced an agreement to acquire BioTelemetry for around $2.8 billion, or $72 per share. BioTelemetry's board approved the transaction and recommended the offer to shareholders; completion was expected in the first quarter of 2021.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/biotelemetry · Editorial policy · How profiles are compiled